Nightstar Therapeutics (NITE) Receives New Coverage from Analysts at Chardan Capital

Equities research analysts at Chardan Capital initiated coverage on shares of Nightstar Therapeutics (NASDAQ:NITE) in a report released on Wednesday, The Fly reports. The brokerage set a “buy” rating on the stock.

A number of other analysts also recently issued reports on NITE. BMO Capital Markets started coverage on shares of Nightstar Therapeutics in a report on Monday, October 23rd. They issued an “outperform” rating and a $30.00 price target on the stock. Jefferies Group began coverage on shares of Nightstar Therapeutics in a report on Monday, October 23rd. They issued a “buy” rating and a $25.00 target price on the stock. Wedbush began coverage on shares of Nightstar Therapeutics in a report on Monday, October 23rd. They issued an “outperform” rating and a $19.00 target price on the stock. Finally, Leerink Swann began coverage on shares of Nightstar Therapeutics in a report on Monday, October 23rd. They issued an “outperform” rating and a $25.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $24.75.

Shares of Nightstar Therapeutics (NITE) traded up $0.09 during midday trading on Wednesday, reaching $13.21. 18,385 shares of the company’s stock were exchanged, compared to its average volume of 29,143. The company has a market cap of $371.21 and a P/E ratio of -26.42. Nightstar Therapeutics has a one year low of $11.99 and a one year high of $24.93.

A number of institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC purchased a new stake in Nightstar Therapeutics in the 3rd quarter valued at about $240,000. Nationwide Fund Advisors purchased a new stake in Nightstar Therapeutics in the 3rd quarter valued at about $1,196,000. Sphera Funds Management LTD. purchased a new stake in Nightstar Therapeutics in the 3rd quarter valued at about $1,728,000. Alyeska Investment Group L.P. bought a new stake in shares of Nightstar Therapeutics in the 3rd quarter valued at about $1,920,000. Finally, Chartwell Investment Partners LLC bought a new stake in shares of Nightstar Therapeutics in the 3rd quarter valued at about $3,995,000. 27.12% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Nightstar Therapeutics (NITE) Receives New Coverage from Analysts at Chardan Capital” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/01/03/nightstar-therapeutics-nite-receives-new-coverage-from-analysts-at-chardan-capital.html.

About Nightstar Therapeutics

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

The Fly

Analyst Recommendations for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply